Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nadia Barraco

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Critical Reviews in Oncology/Hematology|January 16, 2022
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?Daniele Fanale, Lidia Rita Corsini, Raimondo Scalia, et al.
Molecular Oncology|January 9, 2025
On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective studyValerio Gristina, Viviana Bazan, Nadia Barraco, et al.
Critical Reviews in Oncology/Hematology|January 3, 2023
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visibleValerio Gristina, Maria La Mantia, Marta Peri, et al.
Therapeutic Advances in Medical Oncology|February 23, 2023
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplayLorena Incorvaia, Gaetana Rinaldi, Giuseppe Badalamenti, et al.
Cancers|January 8, 2023
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal TumorsAlessandra Dimino, Chiara Brando, Laura Algeri, et al.
Critical Reviews in Oncology/Hematology|November 30, 2023
Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprintsDaniele Fanale, Lidia Rita Corsini, Marco Bono, et al.
Therapeutic Advances in Medical Oncology|October 7, 2021
Not all <i>KIT</i> 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs)Lorena Incorvaia, Giuseppe Badalamenti, Daniele Fanale, et al.
Cancer Treatment Reviews|November 8, 2023
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?Lorena Incorvaia, Alessandro Perez, Claudia Marchetti, et al.
The Oncologist|July 18, 2023
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort StudyLorena Incorvaia, Dario De Biase, Margherita Nannini, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Critical Reviews in Oncology/Hematology|January 16, 2022
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?Daniele Fanale, Lidia Rita Corsini, Raimondo Scalia, et al.
Molecular Oncology|January 9, 2025
On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective studyValerio Gristina, Viviana Bazan, Nadia Barraco, et al.
Critical Reviews in Oncology/Hematology|January 3, 2023
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visibleValerio Gristina, Maria La Mantia, Marta Peri, et al.
Therapeutic Advances in Medical Oncology|February 23, 2023
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplayLorena Incorvaia, Gaetana Rinaldi, Giuseppe Badalamenti, et al.
Cancers|January 8, 2023
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal TumorsAlessandra Dimino, Chiara Brando, Laura Algeri, et al.
Critical Reviews in Oncology/Hematology|November 30, 2023
Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprintsDaniele Fanale, Lidia Rita Corsini, Marco Bono, et al.
Therapeutic Advances in Medical Oncology|October 7, 2021
Not all <i>KIT</i> 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs)Lorena Incorvaia, Giuseppe Badalamenti, Daniele Fanale, et al.
Cancer Treatment Reviews|November 8, 2023
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?Lorena Incorvaia, Alessandro Perez, Claudia Marchetti, et al.
The Oncologist|July 18, 2023
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort StudyLorena Incorvaia, Dario De Biase, Margherita Nannini, et al.
Pageof 4